The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Amedisys met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share expanded.
Gross margins shrank, operating margins dropped, net margins increased.
Amedisys logged revenue of $375.6 million. The 11 analysts polled by S&P Capital IQ anticipated a top line of $380.0 million on the same basis. GAAP reported sales were 0.2% higher than the prior-year quarter's $374.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.33. The 11 earnings estimates compiled by S&P Capital IQ predicted $0.27 per share. GAAP EPS were $0.33 for Q3 compared to -$14.73 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.0%, 210 basis points worse than the prior-year quarter. Operating margin was 3.9%, 60 basis points worse than the prior-year quarter. Net margin was 2.6%, 11,560 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $381.7 million. On the bottom line, the average EPS estimate is $0.25.
Next year's average estimate for revenue is $1.51 billion. The average EPS estimate is $1.02.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 817 members out of 910 rating the stock outperform, and 93 members rating it underperform. Among 220 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 187 give Amedisys a green thumbs-up, and 33 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $13.56.
- Add Amedisys to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Amedisys. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.